Baudax Bio Inc(BXRX)stock report

Baudax Bio, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for acute care settings. The Company’s lead product candidate is IV injectable form of Meloxicam, a long-acting preferential cyclooxygenase (COX)-2 inhibitor. The Company’s product pipeline also includes other early-stage product candidates, including two neuromuscular blocker agents (NMBAs) and a related chemical reversal agent, and Dexmedetomidine (Dex)- intranasal (IN), an intranasal formulation of dexmedetomidine. The Company is developing an intermediate-acting NMBA, RP100; an ultrashort-acting NMBA, RP2000, and a reversal agent specific to its NMBAs.

Finance:
Market Cap:67.7M; Shares Outstanding:9.4M; Q3 2019(9/30/19): Cash 0. Loss 10.31M

EPS and Sales:
https://finance.yahoo.com/quote/BXRX/financials?p=BXRX

Date EPS % last year % last quarter
2018.12.31 / / /
2019.3.31 / / /
2019.6.30 -149170 / /
2019.9.30 -252320 / -69.15%

 

Insider Transactions:
http://insidercow.com/history/company.jsp?company=BXRX&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/BXRX/institutional-ownership/

2019.12.29:
Total institutions: 106,no change
Shares hold: 5440.2k shares. no change
shares% hold: 58.18%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/BXRX/price-targe

Leave a Reply